Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KidCOVE
NCT04796896Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing mRNA-1273 with Placebo (2 arms). Primary endpoints: Solicited Local and Systemic Adverse Reactions, Unsolicited Adverse Events and 3 more. Started Mar 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04796896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796896.